DTech Liquidating

DTech Liquidating Asset Growth

Delisted

The Year-over-Year Total Asset Growth of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is -39.67 %. In the previous year, Year-over-Year Total Asset Growth was -18.61 % — a change of 113.20% (lower).

Asset Growth

-39.67 %

YoY

113.20%

Last updated:

Year-over-Year Total Asset Growth of DTech Liquidating is 2023 -39.67 % . Year-over-Year Total Asset Growth of DTech Liquidating was 2022 -18.61 % . It decreases by 113.20% lower compared to the previous year.

The DTech Liquidating Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2016
0.00 USD
Jan 1, 2017
73,350.00 USD
Jan 1, 2018
-91.56 USD
Jan 1, 2019
46.77 USD
Jan 1, 2020
283.52 USD
Jan 1, 2021
255.73 USD
Jan 1, 2022
-18.61 USD
Jan 1, 2023
-39.67 USD
The DTech Liquidating Asset Growth history
YEARAsset GrowthYoY
-39.67 %+113.20%
-18.61 %-107.28%
255.73 %-9.80%
283.52 %+506.14%
46.77 %-151.09%
-91.56 %-100.12%
73,350.00 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Year-over-Year Total Asset Growth of DTech Liquidating is -39.67 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — DTech Liquidating

All Key Metrics — DTech Liquidating